Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA RECALLS & COURT ACTIONS: August 18, 1993

Executive Summary

CLASS II -- DIAZEPAM, TABLETS 2 mg, in bottles of 100, used for anxiety disorders,. Recall number: D-318-3. Lot numbers: 1532-040, 1532-041. Manufacturer: Lederle Laboratories, Inc., Pearl River, New York. Recalled by: Vanguard Labs, Inc., Glasgow, Kentucky (repacker), by letter July 30, 1993. Firm-initiated recall ongoing. Distribution: Nationwide; 535 boxes were distributed. Reason: A bottle received from the manufacturer labeled as containing 2 mg tablets contained 5 mg tablets. CLASS III -- ACETAMINOPHEN WITH CODEINE TABLETS 300 mg, in 100 tablet unit dose cartons, 5 sheets of 20 unit dose blister packs, and 10 sheets of 10 unit dose blister packs, Rx drug for the relief of mild to moderately severe pain. Recall number: D-313-3. Lot numbers 2F747. Manufacturer: Barr Laboratories, Inc., Northvale, New Jersey. Recalled by: UDL Laboratories, Inc., Rockford Illinois (repacker), by telephone July 9-28, 1993. Firm-initiated recall ongoing. Distribution: Nationwide; 347 unit cartons were distributed; firm estimates 28 cartons remain on the market. Reason: Potency of codeine ingredient not assured through expiration date. CLASS III -- CONEX PLUS TABLETS, ANTIHISTAMINIC/ANALGESIC/ DECONGESTANT In bottles of 1,000, for the temporary symptomatic relief of nasal congestion, mild pain, and fever. Recall number: D-317-2. Lot number 29129 EXP 4/94. Manufacturer: Forest Pharmaceuticals, Inc., Cincinnati, Ohio. Recalled by: Forest Pharmaceuticals, Inc., St. Louis, Missouri, by telephone April 30, 1993. Firm-initiated recall complete. Distribution: Indiana, Pennsylvania, Kentucky, Maine, Tennessee, Iowa, Illinois, New Jersey, Alabama, Arizona, Michigan, Ohio, Missouri; 234 bottles were distributed. Reason: Subpotency of the phenylpropanolamine ingredient. CLASS III -- CONEX D.A., DECONGESTANT/ANTIHISTAMINIC In bottles of 100 and 1,000, for temporary relief of symptoms associated with nasal allergies, sinusitis and rhinitis. Recall number: D-315-3. Lot 10901 EXP 11/93. Manufacturer: Forest Pharmaceuticals, Inc., Cincinnati, Ohio. Recalled by: Forest Pharmaceuticals, Inc., St. Louis, Missouri, by telephone April 30, 1993. Firm-initiated recall complete. Distribution: Nationwide; 1,147 100-tablet bottles and 230 1,000-tablet bottles were distributed. Reason: Subpotency of the phenylpropanolamine ingredient. CLASS III -- QUELTUSS ANTITUSSIVE-EXPECTORANT Packaged in 1,000-tablet bottles, a non-narcotic cough suppressant. Recall number: D-316-3. Lot number 1912 EXP 3/94. Manufacturer: Forest Pharmaceuticals, Inc., Cincinnati, Ohio. Recalled by: Forest Pharmaceuticals, Inc., St. Louis, Missouri, by telephone April 30, 1993. Firm-initiated recall complete. Distribution: California, Indiana, Wisconsin, Ohio, Minnesota, Colorado, Kentucky, Iowa, New York, Illinois, Canada; 186 bottles were distributed. Reason: Subpotency of the dextromethorphan ingredient. CLASS III -- SULFISOXAZOLE/PHENAZOPYRIDINE HCL 500 mg/50 mg labeled as Azo-Gulfasin, Major label; Sulfisoxazole and Phenazopyridine HCI 500 mg/50 mg, Trinity label; Azo-Sulfisoxazole, Qualitest label, in bottles of 100 and 1,000, for initial treatment of uncomplicated urinary tract infections. Recall number: D-314-3. Lot numbers: C119D, C120D, D121D, D111D, D110D, D124D. Manufacturer: Manufacturing Chemists, Inc., Indianapolis, Indiana. Recalled by: Trinity Technologies Corporation, Roseville, Michigan, by letter July 27, 1993. Firm-initiated recall ongoing. Distribution: Alabama; 60 100-tablet bottles, Lot C119D, (Major label); 1,307 100-tablet bottles, Lot C119D, (Trinity label); 1,097 100-tablet bottles, Lot C120D, (Trinity label); 68 1,000-tablet bottles, Lot D111D, (Major label); 1,247 100-tablet bottles, Lot D110D, (Trinity label); 2,437 100-tablet bottles, Lot C124D, (Qualitest label) were distributed. Reason: Product marketed without new drug approval.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS023176

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel